Bladder Cancer Medications

*generic version available

E experimental

Chemotherapy Medications Learn more >> More >>

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy</td>
<td>Multiple</td>
<td>Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, <a href="#">click here</a>.</td>
</tr>
</tbody>
</table>

Immunotherapy Medications Learn more >> More >>

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bavencio</td>
<td>avelumab</td>
<td>Bavencio is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer, metastatic Merkel cell carcinoma and advanced kidney cancer (renal cell carcinoma).</td>
</tr>
<tr>
<td>Imfinzi</td>
<td>durvalumab</td>
<td>Imfinzi is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer and inoperable non-small-cell lung cancer.</td>
</tr>
<tr>
<td>Keytruda</td>
<td>pembrolizumab</td>
<td>Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency genetic mutations.</td>
</tr>
<tr>
<td>DRUG</td>
<td>GENERIC NAME</td>
<td>DRUG INDICATION</td>
</tr>
<tr>
<td>--------</td>
<td>----------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Opdivo</td>
<td>nivolumab</td>
<td>Opdivo is a checkpoint inhibitor approved for advanced or metastatic melanoma, metastatic non-small-cell lung cancer, advanced and intermediate or poor risk kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, metastatic bladder (urothelial) cancer, liver cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.</td>
</tr>
<tr>
<td>Tecentriq</td>
<td>atezolizumab</td>
<td>Tecentriq is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small cell lung cancer and triple-negative breast cancer.</td>
</tr>
<tr>
<td>TICE</td>
<td>Bacillus Calmette-Guerin</td>
<td>TICE is BCG bacteria approved to treat early-stage bladder (urothelial) cancer and prevent recurrence.</td>
</tr>
</tbody>
</table>

**Targeted Therapy Medications Learn more >> More >>**

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balversa</td>
<td>erdafitinib</td>
<td>Balversa is a kinase inhibitor approved for previously treated locally advanced or metastatic bladder cancer (urothelial carcinoma) that carries FGFR genetic mutations.</td>
</tr>
<tr>
<td>Padcev</td>
<td>enfortumab vedotin-ejfv</td>
<td>Padcev is an antibody-drug conjugate approved for adults with locally advanced or metastatic bladder cancer and other urothelial cancers who previously received PD-1 or PD-L1 checkpoint inhibitors and platinum-based chemotherapy.</td>
</tr>
<tr>
<td>Rozlytrek</td>
<td>entrectinib</td>
<td>Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.</td>
</tr>
<tr>
<td>Vitrakvi</td>
<td>larotrectinib</td>
<td>Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.</td>
</tr>
</tbody>
</table>

**DRUG Chemotherapy**
**GENERIC NAME** Multiple
DRUG Chemotherapy
DRUG INDICATION
Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Bavencio
GENERIC NAME avelumab
DRUG INDICATION
Bavencio is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer, metastatic Merkel cell carcinoma and advanced kidney cancer (renal cell carcinoma).

DRUG Imfinzi
GENERIC NAME durvalumab
DRUG INDICATION
Imfinzi is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer and inoperable non-small-cell lung cancer.

DRUG Keytruda
GENERIC NAME pembrolizumab
DRUG INDICATION
Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG Opdivo
GENERIC NAME nivolumab
DRUG INDICATION
Opdivo is a checkpoint inhibitor approved for advanced or metastatic melanoma, metastatic non-small-cell lung cancer, advanced and intermediate or poor risk kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, metastatic bladder (urothelial) cancer, liver cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG Tecentriq
GENERIC NAME atezolizumab
DRUG INDICATION
Tecentriq is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small cell lung cancer and triple-negative breast cancer.

DRUG TICE
GENERIC NAME Bacillus Calmette-Guerin
**DRUG TICE**
**DRUG INDICATION**
TICE is BCG bacteria approved to treat early-stage bladder (urothelial) cancer and prevent recurrence.

**DRUG Balversa**
**GENERIC NAME** erdafitinib
**DRUG INDICATION**
Balversa is a kinase inhibitor approved for previously treated locally advanced or metastatic bladder cancer (urothelial carcinoma) that carries FGFR genetic mutations.

**DRUG Padcev**
**GENERIC NAME** enfortumab vedotin-ejfv
**DRUG INDICATION**
Padcev is an antibody-drug conjugate approved for adults with locally advanced or metastatic bladder cancer and other urothelial cancers who previously received PD-1 or PD-L1 checkpoint inhibitors and platinum-based chemotherapy.

**DRUG Rozlytrek**
**GENERIC NAME** entrectinib
**DRUG INDICATION**
Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

**DRUG Vitrakvi**
**GENERIC NAME** larotrectinib
**DRUG INDICATION**
Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.